Increased incidence of another cancer in myeloproliferative neoplasms patients at the time of diagnosis

Helna Pettersson(NU Hospital Group), Björn Andréasson(NU Hospital Group), Erik Holmberg(University of Gothenburg), Håvar Knutsen(Akershus University Hospital)

European Journal Of Haematology

July 5, 2014

10.1111/ejh.12410

Cited by 39

Related Papers

Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs

|Journal of Clinical Oncology|2012|461

Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome–positive leukemia

|Blood|2008|447

The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients

|Blood|2011|340

Treatment-Related Risk Factors for Transformation to Acute Myeloid Leukemia and Myelodysplastic Syndromes in Myeloproliferative Neoplasms

|Journal of Clinical Oncology|2011|244

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

|The Lancet|2023|194